Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ulu Kadir, Aliyev Emil, Kılıç Könte Elif, Tanatar Ayşe, Türkmen Şeyma, Doğantan Şeyda, Kızıldağ Zehra, Kasap Demir Belde, Gezgin Yıldırım Deniz, Otar Yener Gülçin, Öztürk Kübra, Baba Özge, Açarı Ceyhun, Kılbaş Gülşah, Taşkın Sema Nur, Haşlak Fatih, Çağlayan Şengül, Bağlan Esra, Dundar Hatice Adıgüzel, Başaran Özge, Barut Kenan, Karadağ Şerife Gül, Coşkuner Taner, Sönmez Hafize Emine, Yüksel Selçuk, Kalyoncu Mukaddes, Bakkaloğlu Sevcan A, Ünsal Erbil, Paç Kısaarslan Ayşenur, Bilginer Yelda, Aktay Ayaz Nuray, Kasapçopur Özgür, Özen Seza, Sözeri Betül
Аннотация
METHODS: Demographic, clinical and laboratory data of patients followed up with a diagnosis of sJIA-associated MAS assessed from sixteen paediatric rheumatology centres across the country. The clinical and laboratory features of MAS developing while on biological drugs were compared with those without this treatment.
RESULTS: One hundred and sixty-two patients were included in the study. Forty-five of the MAS events were detected under the effect of anti-IL-1/-6 biologics, while the patients experiencing the remaining 155 events have not received biological treatment in the last three months. Platelet count [128 (72-232) vs 199 (130-371) 109/l], ferritin level on admission [1107 (676-2050) vs 2863 (1193-9562) ng/ml], C-reactive protein level [15.4 (2.9-56) vs 90 (32-160) mg/l], erythrocyte sedimentation rate [13 (3-36) vs 43.5 (13-77) mm/h] and fever duration [5 (4-7.5) vs 10 (7-14.3) days] were found lower in the group under the impact of anti-IL-1/-6 biologics. Among patients treated with biologics, 26.6% did not meet the published 2016 MAS classification criteria at presentation. The rates of hepatomegaly and splenomegaly were relatively lower in the canakinumab-treated group when compared with those receiving other biologicals or to patients, not on biologicals.
CONCLUSION: Anti-IL-1/-6 therapies can mask the clinical and laboratory features of MAS, and proposed guidelines for MAS classification criteria may not be met.